ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

516
Analysis
Health Care • China
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
bullish•Geekplus Technology
•23 Nov 2025 06:05

[Quiddity Index] Dec25 Hang Seng Index Family Review; Flows for December 5 Rebal

The Hang Seng Index family announced its December rebalance changes on Friday after the close. Here we show the changes and flows across 6 major...

Logo
636 Views
Share
•20 Nov 2025 09:44

Jiangsu Hengrui Pharma IPO Lockup - US$850m Cornerstone Release

Jiangsu Hengrui Pharmaceuticals (1276 HK), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing in May 2025. The...

Logo
429 Views
Share
bullish•BeiGene
•18 Nov 2025 12:38

Quiddity Leaderboard Hang Seng Index Dec25: BeOne, Innovent, & Other Potential Surprises

The Hang Seng index December 2025 index review results will be announced after market close on Friday 21st November 2025. It might be a good time...

Share
bullish•Quantitative Analysis
•16 Nov 2025 10:05

HK Connect Flows Weekly (Nov 14th): Alibaba, Xiaomi, CNOOC, ICBC, Ping An Insurance, Petrochina

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Xiaomi, CNOOC, ICBC, Ping An Insurance, Petrochina.

Logo
558 Views
Share
bullish•Yum China Holdings
•10 Nov 2025 16:52

Quiddity Leaderboard HSCEI Dec25: Three Index Change Possible; ~US$264mn One-Way; Announcement Soon

We continue to expect Yum China Holdings (9987 HK) to outperform Haidilao International Holding (6862 HK) over the next few weeks.

Share
x